JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB212089

Anti-CD272/BTLA antibody [EPR20539]

Be the first to review this product! Submit a review

|

(3 Publications)

Rabbit Recombinant Monoclonal CD272/BTLA antibody. Suitable for IP, Flow Cyt, WB, ICC/IF and reacts with Mouse samples. Cited in 3 publications.

View Alternative Names

CD272, B- and T-lymphocyte attenuator, B- and T-lymphocyte-associated protein, Btla

5 Images
Immunocytochemistry/ Immunofluorescence - Anti-CD272/BTLA antibody [EPR20539] (AB212089)
  • ICC/IF

Lab

Immunocytochemistry/ Immunofluorescence - Anti-CD272/BTLA antibody [EPR20539] (AB212089)

Immunofluorescent analysis of 100% methanol fixed A20 (mouse reticulum sarcoma cell line) cells labeling CD272/BTLA with ab212089 at 1/100 dilution, followed by by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution (green). Confocal image showing cytoplasmic and membranous staining on A20 cell line.

The nuclear counter stain is DAPI (blue). Tubulin is detected with Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor® 594) (ab195889) (red) at 1/200 dilution.

Secondary antibody only control : Used PBS instead of primary antibody, secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) (ab150077) secondary antibody at 1/1000 dilution.

Flow Cytometry - Anti-CD272/BTLA antibody [EPR20539] (AB212089)
  • Flow Cyt

Lab

Flow Cytometry - Anti-CD272/BTLA antibody [EPR20539] (AB212089)

Flow cytometric analysis of A20 (mouse reticulum sarcoma cell line) cell line labeling CD272/BTLA with ab212089 at 1/500 dilution (red) compared with a Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (black) and an unlabeled control (cells without incubation with primary antibody and secondary antibody) (blue). Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) at 1/2000 dilution was used as the secondary antibody.

Total viable cells were gated for the FC image.

Flow Cytometry - Anti-CD272/BTLA antibody [EPR20539] (AB212089)
  • Flow Cyt

Lab

Flow Cytometry - Anti-CD272/BTLA antibody [EPR20539] (AB212089)

Flow cytometric analysis of mouse splenocytes labeling CD272/BTLA with ab212089 at 1/500 dilution (right) compared with a Rabbit IgG, monoclonal [EPR25A] - Isotype Control (ab172730) (left). Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) at 1/2000 dilution was used as the secondary antibody.

Mouse splenocytes stained with CD3 and ab212089. Total viable cells were gated for the FC image. T cells (CD3+, upper population) show a moderate positive signal while B cells (lower right population in right panel) show stronger positive signal. The expression pattern is also reported in literature (PMID : 19949073).

Immunoprecipitation - Anti-CD272/BTLA antibody [EPR20539] (AB212089)
  • IP

Lab

Immunoprecipitation - Anti-CD272/BTLA antibody [EPR20539] (AB212089)

CD272/BTLA was immunoprecipitated from 0.35 mg mouse spleen lysate with ab212089 at 1/30 dilution. Western blot was performed from the immunoprecipitate using ab212089 at 1/500 dilution. VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/1000 dilution

Lane 1 : Mouse spleen lysate 10 μg (Input).

Lane 2 : ab212089 IP in mouse spleen lysate.

Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab212089 in mouse spleen lysate.

Blocking and dilution buffer and concentration : 5% NFDM/TBST.

Exposure time : 1 second.

All lanes:

Immunoprecipitation - Anti-CD272/BTLA antibody [EPR20539] (ab212089)

Predicted band size: 33 kDa

false

Exposure time: 1s

Western blot - Anti-CD272/BTLA antibody [EPR20539] (AB212089)
  • WB

Lab

Western blot - Anti-CD272/BTLA antibody [EPR20539] (AB212089)

Exposure time : Lane 1 : 5 seconds; Lanes 2-3 : 30 seconds.

Blocking/Dilution buffer : 5% NFDM/TBST.

Lane 1:

Western blot - Anti-CD272/BTLA antibody [EPR20539] (ab212089) at 1/10000 dilution

Lanes 2 - 3:

Western blot - Anti-CD272/BTLA antibody [EPR20539] (ab212089) at 1/1000 dilution

Lane 1:

A20 (mouse reticulum sarcoma cell line) whole cell lysate at 20 µg

Lane 2:

Mouse spleen lysate at 20 µg

Lane 3:

Mouse lymph node lysate at 20 µg

Secondary

All lanes:

Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution

Predicted band size: 33 kDa

Observed band size: 55-70 kDa

true

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR20539

Isotype

IgG

Carrier free

No

Reacts with

Mouse

Applications

Flow Cyt, ICC/IF, IP, WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Mouse": { "IP-species-checked": "testedAndGuaranteed", "IP-species-dilution-info": "1/30", "IP-species-notes": "<p></p>", "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "1/500", "FlowCyt-species-notes": "<p></p>", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000", "WB-species-notes": "<p></p>", "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/100", "ICCIF-species-notes": "<p></p>" } } }

Product details

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage duration
1-2 weeks
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CD272 also known as BTLA (B and T Lymphocyte Attenuator) is an immunoregulatory protein with a mass approximately 34 kDa. This target is part of the CD28 immunoglobulin superfamily and is expressed on the surfaces of various immune cells including T cells B cells and dendritic cells. BTLA/CD272 serves as a co-inhibitory molecule important in maintaining immune homeostasis. Its expression is influenced by factors present in the microenvironment of immune tissues.
Biological function summary

BTLA functions as a negative regulator of immune responses by delivering inhibitory signals to immune cells upon binding to its ligand HVEM (Herpesvirus entry mediator). It forms a part of an immunological checkpoint complex that modulates lymphocyte activity to prevent overactivation and autoimmunity. This mechanism helps maintain a balance between immune defense and tolerance contributing to self-tolerance.

Pathways

The BTLA/CD272 protein engages with pathways involved in immune checkpoints and T-cell receptor signaling. It interacts with proteins like HVEM and collaborates with receptors such as PD-1 and CTLA-4. These interactions play a role in the downregulation of T-cell responses which is essential in various immune processes. The signaling pathways influenced by BTLA/CD272 are integral in moderating immune responses cooperation and adaptation.

BTLA is associated with autoimmune diseases and cancer. In autoimmune disorders an altered expression or function of BTLA can lead to dysregulated immune responses causing tissue damage. In cancer the protein may contribute to immune evasion by tumors aiding tumor growth and progression. The interplay of BTLA with proteins such as PD-1 makes it a potential target for immunotherapy strategies in oncology and autoimmunity treatments.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2 (PubMed : 12796776, PubMed : 14652006). May interact in cis (on the same cell) or in trans (on other cells) with TNFRSF14 (PubMed : 19915044). In cis interactions, appears to play an immune regulatory role inhibiting in trans interactions in naive T cells to maintain a resting state. In trans interactions, can predominate during adaptive immune response to provide survival signals to effector T cells (PubMed : 19915044).
See full target information Btla

Publications (3)

Recent publications for all applications. Explore the full list and refine your search

iScience 28:113485 PubMed41019372

2025

Comparative effects of hemodialysis modalities on microparticle induction and neutrophil activation in a randomized cross-over study.

Applications

Unspecified application

Species

Unspecified reactive species

Awirut Charoensappakit,Jirarat Eiamcharoenying,Kritsanawan Sae-Khow,Suwasin Udomkarnjananun,Khajohn Tiranathanagul,Asada Leelahavanichkul

Journal for immunotherapy of cancer 13: PubMed40081944

2025

promoter hypomethylation correlates with enhanced immune cell infiltration, favorable prognosis, and immunotherapy response in melanoma.

Applications

Unspecified application

Species

Unspecified reactive species

Minglei Yang,Chenxi Zheng,Yu Miao,Cuicui Yin,Longfei Tang,Chongli Zhang,Pu Yu,Qingfang Han,Yihui Ma,Shenglei Li,Guozhong Jiang,Wencai Li,Peiyi Xia

Science China. Life sciences 65:1917-1928 PubMed35918604

2022

PDGFR kinase inhibitor protects against septic death via regulation of BTLA.

Applications

Unspecified application

Species

Unspecified reactive species

Qiang Wang,Jin Deng,Jianhui Sun,Huacai Zhang,Di Liu,Chu Gao,Jinchao Qiu,Wenyi Liu,Guoxin Qu,Dalin Wen,Juan Du,Anqiang Zhang,Ling Zeng,Jianxin Jiang
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com